Shares of Senseonics Holdings, Inc. (SENS) surged 11.52% in after-hours trading on Wednesday, following the company's announcement of operational and financial updates, including the successful launch of its Eversense 365 continuous glucose monitoring (CGM) system and a positive outlook for 2025.
Senseonics reported preliminary unaudited fourth-quarter revenue of approximately $8.3 million and full-year 2024 revenue of around $22.5 million. The company highlighted several key achievements in 2024, including receiving FDA approval for and launching the Eversense 365 CGM system in collaboration with its commercial partner, Ascensia.
The launch of Eversense 365, which can monitor glucose levels for up to 365 days with a single implantable sensor, has been met with strong early interest. Senseonics noted a doubling of direct-to-consumer leads in Q4 compared to Q3, a record high of approximately 600 new patient shipments in December, a 49% increase in patients switching from competitive CGM systems, and a 118% surge in physician referrals since the launch.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.